Non-selective dopamine and norepinephrine transporter (DAT/NET) inhibitor (Kivalues are 1.4, 2.8 and 45μM for NET, DAT and SERT transporters respectively). Nicotinic acetylcholine receptor (nAchrs) antagonist (IC50= are 1.8 at α2β2receptor). Displays anti-depressant activity.
Useful References
Dwoskin et al(2006) Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev. 12:178-207.abstract
Budzynska et al(2011) Effects of bupropion on the reinstatement of nicotine-induced conditioned place preference by drug priming in rats. Pharmacol Rep. 63:362-71.abstract
Damaj et al(2004) Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol. 66:675-82.abstract